Drug spin-off trend gains traction with IPO by Hengrui offshoot
A company set up to develop Hengrui Pharma’s weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the “NewCo” business model Key Takeaways: Hengrui’s…
FAST NEWS: Everest Medicines loss widens on drug commercialization
The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
